[Ip-health] New Tufts study on R&D costs

Jamie Love james.love at keionline.org
Fri Nov 14 13:14:22 PST 2014


It will be interesting to see what "cost of capital" figures Tufts uses
this year.

Recently Gilead priced a series of bonds, $500 million at $2.35
percent maturing February 2020, $1,750M at 3.5 percent maturing February
2025 and $1,750M at 4.5 percent maturing February 2045.



More information about the Ip-health mailing list